Israel Meizner , Sofer Mira , Naheed Visram & Dr. Ronit Shtrichman
1. Rabin Medical Center, Petah Tikva, Israel.
2 Pulsenmore Ltd., Israel.
3 Pulsenmore, United Kingdom
Telehealth has become a transformative force in prenatal care, enhancing maternal satisfaction, reducing costs, and increasing efficiency without compromising safety or outcomes. The Pulsenmore home ultrasound is a handheld device connected to smartphones and guided by a mobile app, enables women to perform high-quality ultrasound scans at home. These scans are securely transmitted to clinicians, enabling a hybrid care model that combines remote monitoring with in-clinic expertise. Several studies have validated the Pulsenmore device’s feasibility, safety, and user acceptance:
Clinical evidence
A study with 100 pregnant women demonstrated its effectiveness in detecting fetal heartbeat, movement, and amniotic fluid volume (AFV), with high satisfaction . A pivotal multicenter study in the USA confirmed these results. Real-world data in Israel showed over 98% precision in detecting prenatal parameters across 150,000+ scans.
In Germany, studies confirmed the device’s acceptance and image quality for assessing AFV and fetal heartbeat, showing high patient satisfaction and potential to reduce outpatient visits .
Validation studies confirmed the device’s reliability and accuracy in measuring fetal heart rate and maximal vertical pocket , as well as its capability to conduct remote Biophysical Profile tests for high-risk pregnancies.
The device’s potential was demonstrated in monitoring high-risk pregnancies, reducing anxiety and ER visits for women with previous pregnancy loss , and managing gestational diabetes . Real-world utilization data indicate successful home admission of women with high-risk pregnancies.
Conclusion:
The Pulsenmore platform offers a safe, effective, and patient-centered solution for prenatal monitoring. Clinical evidence from three years of research and successful commercialization supports its integration into prenatal care.
